LU81687A1 - Vaccin combine contre la maladie de newcastle et la chute de ponte provoquee par des virus adeno-like - Google Patents

Vaccin combine contre la maladie de newcastle et la chute de ponte provoquee par des virus adeno-like Download PDF

Info

Publication number: LU81687A1
Authority: LU; Luxembourg
Prior art keywords: virus; adeno; liquid containing; culture; newcastle disease
Prior art date: 1978-09-14

Application number

LU81687A

Other languages

English (en)

French (fr)

Inventor

P Apontoweil

J Kok

Original Assignee

Gist Brocades Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-09-14

Filing date

1979-09-14

Publication date

1981-04-17

1979-09-14 Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv

1981-04-17 Publication of LU81687A1 publication Critical patent/LU81687A1/fr

Links

241000700605 Viruses Species 0.000 title claims description 111
208000010359 Newcastle Disease Diseases 0.000 title claims description 13
229960005486 vaccine Drugs 0.000 title description 46
239000007788 liquid Substances 0.000 claims description 63
239000000725 suspension Substances 0.000 claims description 31
241000711404 Avian avulavirus 1 Species 0.000 claims description 26
208000015181 infectious disease Diseases 0.000 claims description 20
239000012071 phase Substances 0.000 claims description 19
238000000034 method Methods 0.000 claims description 18
241000287828 Gallus gallus Species 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 16
210000004027 cell Anatomy 0.000 claims description 15
230000002458 infectious effect Effects 0.000 claims description 15
235000013601 eggs Nutrition 0.000 claims description 14
230000035931 haemagglutination Effects 0.000 claims description 13
210000001161 mammalian embryo Anatomy 0.000 claims description 13
241000272525 Anas platyrhynchos Species 0.000 claims description 12
239000000470 constituent Substances 0.000 claims description 12
239000002609 medium Substances 0.000 claims description 12
239000000839 emulsion Substances 0.000 claims description 11
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
239000008346 aqueous phase Substances 0.000 claims description 9
210000002950 fibroblast Anatomy 0.000 claims description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 claims description 7
238000004113 cell culture Methods 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 7
210000002966 serum Anatomy 0.000 claims description 7
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 6
244000309466 calf Species 0.000 claims description 6
229960000380 propiolactone Drugs 0.000 claims description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
239000002480 mineral oil Substances 0.000 claims description 5
238000005096 rolling process Methods 0.000 claims description 5
229910019142 PO4 Inorganic materials 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
239000003995 emulsifying agent Substances 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
238000011534 incubation Methods 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
241000283690 Bos taurus Species 0.000 claims description 3
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
125000002947 alkylene group Chemical group 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
230000000120 cytopathologic effect Effects 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
150000004665 fatty acids Chemical class 0.000 claims description 3
239000001963 growth medium Substances 0.000 claims description 3
238000012423 maintenance Methods 0.000 claims description 3
229940056360 penicillin g Drugs 0.000 claims description 3
239000002356 single layer Substances 0.000 claims description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
229960005322 streptomycin Drugs 0.000 claims description 3
235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
239000008158 vegetable oil Substances 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
229960003255 natamycin Drugs 0.000 claims description 2
NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 2
239000004311 natamycin Substances 0.000 claims description 2
235000010298 natamycin Nutrition 0.000 claims description 2
239000003921 oil Substances 0.000 claims description 2
235000019198 oils Nutrition 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
230000002335 preservative effect Effects 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
239000003381 stabilizer Substances 0.000 claims description 2
241000701161 unidentified adenovirus Species 0.000 claims description 2
229940031551 inactivated vaccine Drugs 0.000 claims 7
230000000937 inactivator Effects 0.000 claims 2
-1 ester ethers Chemical class 0.000 claims 1
235000013305 food Nutrition 0.000 claims 1
239000002736 nonionic surfactant Substances 0.000 claims 1
239000004094 surface-active agent Substances 0.000 claims 1
235000013330 chicken meat Nutrition 0.000 description 14
241000271566 Aves Species 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 8
244000144977 poultry Species 0.000 description 8
235000013594 poultry meat Nutrition 0.000 description 8
230000002779 inactivation Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000007170 pathology Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
229920000136 polysorbate Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
206010006451 bronchitis Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000000265 homogenisation Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
244000052769 pathogen Species 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
239000012984 antibiotic solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
206010064097 avian influenza Diseases 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
229940001442 combination vaccine Drugs 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000003067 hemagglutinative effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
125000006353 oxyethylene group Chemical group 0.000 description 1
239000010690 paraffinic oil Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
230000007482 viral spreading Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
229960004854 viral vaccine Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

LU81687A 1978-09-14 1979-09-14 Vaccin combine contre la maladie de newcastle et la chute de ponte provoquee par des virus adeno-like LU81687A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
NL7809364		1978-09-14
NL7809364		1978-09-14
NL7903300		1979-04-26
NL7903300		1979-04-26

Publications (1)

Publication Number	Publication Date
LU81687A1 true LU81687A1 (fr)	1981-04-17

Family

ID=26645447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU81687A LU81687A1 (fr)	1978-09-14	1979-09-14	Vaccin combine contre la maladie de newcastle et la chute de ponte provoquee par des virus adeno-like

Country Status (10)

Country	Link
US (1)	US4537768A (da)
EP (1)	EP0009277B1 (da)
DE (1)	DE2966914D1 (da)
DK (1)	DK157732C (da)
ES (2)	ES484187A1 (da)
FR (1)	FR2435949A1 (da)
GR (1)	GR70272B (da)
IE (1)	IE48482B1 (da)
LU (1)	LU81687A1 (da)
PT (1)	PT70156A (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7812359A (nl) *	1978-12-20	1980-06-24	Gist Brocades Nv	Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
SU826584A1 (ru) *	1979-10-29	1982-11-07	Всесоюзный государственный научно-контрольный институт ветеринарных препаратов	Вакцина против ньюкаслской болезни птиц,способ ее изготовлени и способ профилактики ньюкаслской болезни птиц
US5084271B1 (en) *	1984-09-11	1997-08-05	Univ Melbourne	Vaccine for equine herpesvirus
US4613501A (en) *	1984-12-21	1986-09-23	New York Blood Center, Inc.	Inactivation of viruses in labile blood derivatives
ES2060740T3 (es) *	1988-07-18	1994-12-01	Duphar Int Res	Vacunas de virus vivos para la enfermedad de newcastle.
FR2706665B1 (fr) *	1993-06-11	1995-09-08	Fis	Dispositif pour la fixation d'un boîtier d'affichage électronique.
RU2167673C1 (ru) *	2000-09-04	2001-05-27	Всероссийский научно-исследовательский институт защиты животных	Набор для определения антител к вирусу синдрома снижения яйценоскости-76 кур

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL292949A (da) *
US3083142A (en) *	1958-02-27	1963-03-26	Glaxo Group Ltd	Improved swine erysipelas vaccine
US3060094A (en) *	1959-04-07	1962-10-23	Ray M Dutcher	Preparation of virus vaccines
US3149036A (en) *	1961-10-16	1964-09-15	Merck & Co Inc	Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent
US3399263A (en) *	1965-04-12	1968-08-27	American Cyanamid Co	Stable adjuvant emulsion compositions comprising the hydrated reaction products of a methallic cation and a fatty acid
US3678149A (en) *	1970-01-26	1972-07-18	Samuel J Prigal	Method of enhancing the action of a medicament
NL7012832A (da) *	1970-08-29	1972-03-02
US3876763A (en) *	1970-12-29	1975-04-08	Shionogi & Co	Infectious coryza infectious bronchitis and newcastle disease vaccines and production thereof
US3906092A (en) *	1971-11-26	1975-09-16	Merck & Co Inc	Stimulation of antibody response
JPS529727B2 (da) *	1971-12-29	1977-03-18
JPS506714A (da) *	1973-05-31	1975-01-23
US3983228A (en) *	1973-08-28	1976-09-28	Merck & Co., Inc.	Water-in-oil adjuvant composition
US4069313A (en) *	1974-11-19	1978-01-17	Merck & Co., Inc.	Water-in-oil adjuvant composition
US4073743A (en) *	1975-04-17	1978-02-14	Merck & Co., Inc.	Process for preparing an emulsion
JPS529727A (en) *	1975-07-11	1977-01-25	Toyota Motor Corp	Carburettor
GB1590448A (en) *	1977-03-04	1981-06-03	Akzo Nv	Vaccine and its preparations

1979
- 1979-09-05 EP EP79200490A patent/EP0009277B1/en not_active Expired
- 1979-09-05 DE DE7979200490T patent/DE2966914D1/de not_active Expired
- 1979-09-10 PT PT70156A patent/PT70156A/pt unknown
- 1979-09-11 GR GR60010A patent/GR70272B/el unknown
- 1979-09-13 DK DK383079A patent/DK157732C/da not_active IP Right Cessation
- 1979-09-13 IE IE1745/79A patent/IE48482B1/en unknown
- 1979-09-14 FR FR7923026A patent/FR2435949A1/fr active Granted
- 1979-09-14 LU LU81687A patent/LU81687A1/fr unknown
- 1979-09-14 ES ES484187A patent/ES484187A1/es not_active Expired
- 1979-10-17 ES ES485105A patent/ES485105A1/es not_active Expired
1982
- 1982-03-11 US US06/356,952 patent/US4537768A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK157732B (da)	1990-02-12
DE2966914D1 (en)	1984-05-24
IE791745L (en)	1980-03-14
FR2435949A1 (fr)	1980-04-11
PT70156A (en)	1979-10-01
US4537768A (en)	1985-08-27
EP0009277A1 (en)	1980-04-02
DK157732C (da)	1990-07-09
IE48482B1 (en)	1985-02-06
ES485105A1 (es)	1980-06-16
DK383079A (da)	1980-03-15
GR70272B (da)	1982-09-03
EP0009277B1 (en)	1984-04-18
FR2435949B1 (da)	1984-05-18
ES484187A1 (es)	1980-04-01

Publication	Publication Date	Title
EP1232249B1 (fr)	2004-07-07	Pneumovirus du canard et vaccins correspondants
CA1204055A (en)	1986-05-06	Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain
FR2602791A1 (fr)	1988-02-19	Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
LU81687A1 (fr)	1981-04-17	Vaccin combine contre la maladie de newcastle et la chute de ponte provoquee par des virus adeno-like
US4505892A (en)	1985-03-19	Infectious bronchitis vaccine for poultry
LU82018A1 (fr)	1981-07-23	Vaccins contre des maladies provoquees par des reovirus et procede de preparation de ces vaccins
RU2378014C2 (ru)	2010-01-10	Ассоциированная вакцина против парагриппа-3, инфекционного ринотрахеита и коронавирусной инфекции крупного рогатого скота эмульсионная инактивированная
CN106822886A (zh)	2017-06-13	鸡传染性法氏囊和禽腺病毒4型二联灭活疫苗的制备方法
EP2550015B1 (fr)	2017-02-22	Vaccin vivant pour maladies aviaires
EP0029047A1 (en)	1981-05-27	Combined inactivated vaccine, ready for administration and process for the preparation of such vaccine, active against egg production drop caused by adeno like viruses and against diseases caused by reo viruses
CH382917A (fr)	1964-10-15	Procédé pour la production d'un virus-vaccin contre la maladie des chiens
CN102352345B (zh)	2013-05-22	一种新城疫hi抗原的制备方法
BE878804A (fr)	1980-03-14	Vaccin combine contre la maladie de newcastle et le chute de ponte provoquee par des virus adeno-like
US4515777A (en)	1985-05-07	Vaccines
JPS6244528B2 (da)	1987-09-21
WO2002080840A2 (fr)	2002-10-17	Adjuvant d'immunite contenant un cation metallique complexe et vaccin le contenant
RU2480238C1 (ru)	2013-04-27	Вакцина ассоциированная против ньюкаслской болезни, реовирусного теносиновита и метапневмовирусной инфекции птиц инактивированная эмульсионная
EP0186368B1 (en)	1991-04-03	Biological preparations
US3629396A (en)	1971-12-21	Avian encephalomyelitis vaccine
NL7906696A (nl)	1980-03-18	Kant en klaar, gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen pseudovogelpest en door adeno achtige virussen veroorzaakte eiproduktiedalingen.
USRE34013E (en)	1992-07-28	Infectious bronchitis vaccine for poultry
WO2002089762A1 (fr)	2002-11-14	Emulsion e/h concentree
GB2048669A (en)	1980-12-17	Canine distemper vaccines